Phase I/II feasibility study of cetuximab with cisplatin or 5FU and Mitomycin C with concurrent radiotherapy in muscle invasive bladder cancer (TUXEDO)
Combining radiotherapy with drug therapy has produced impressive outcome gains in a number of cancers includingbladder cancer. We aim to combine radiotherapy (a current standard treatment) with a new drug cetuximab as well asstandard chemotherapy drugs either fluorouracil with mitomycin C or cisplatin. We will initially evaluate the safety of thecombinations. Subject to satisfactory safety data we will go on to study the preliminary efficacy of the combinationtherapy as a basis for future trials.
|PI Name||James - ND|
|Sponsor||University of Birmingham|
|Proposed End Date||30/06/2017|
|Study Run through CRF?||Yes|
|Target number of patients agreed to recruit||18|
|Recruitment so far||9|